Lindus Therapeutics, backed by Peter Thiel, is pivoting away from its CRO roots to pursue drug development and hunt for drug assets. The transatlantic startup had branded itself as an “anti-CRO” and now is reallocating resources toward pipeline-building rather than operating as a clinical trials services provider. The pivot highlights how some small operators are attempting to capture more value by moving closer to asset ownership, particularly in crowded oncology and metabolic areas. The transition will also change how Lindus funds programs and selects licensing or partnering opportunities.